Controversies over the indication of chloroquine and hydroxychloroquine for the treatment of covid-19
DOI:
https://doi.org/10.19180/1809-2667.v25n12023.17147Keywords:
coronavirus, covid-19, chloroquine, hydroxychloroquine, azithromycinAbstract
The global health crisis caused by the new coronavirus pandemic represents a moment of uncertainty. Due to the rapid spread of the virus and the absence of an appropriate contingency plan, some drugs began to be used preventively: chloroquine, hydroxychloroquine, and azithromycin, especially in the fight against opportunistic infections such as pneumonia. However, the indication of these drugs quickly became controversial. The objective of this research was to conduct a literature review on the controversies of the indication of chloroquine and hydroxychloroquine, associated or not, to azithromycin for the treatment of covid-19. The methodology used was the narrative review of the literature conducted from March 2020 to March 2021. The different authors were unanimous in stating that due to the difficulties imposed, there are great barriers to proving the use of chloroquine and hydroxychloroquine, both due to the uncertainty of the research published so far and the dubious or even questionable quality of the methodologies used. It is concluded that to date there is no specific treatment for covid-19 due to the absence of robust results. Therefore, the scientific community will oppose the use of these two drugs until data from well-designed clinical trials are published, with a greater number of participants, clearer methodologies, and more consistent results.Downloads
References
BORBA, M. G. S. et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. A Randomized Clinical Trial. JAMA Netw Open, v. 3, n. 4, e208857, 2020. DOI: https://doi.org/10.1001/jamanetworkopen.2020.8857. Disponível em: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2765499. Acesso em: 9 fev. 2023.
BRASIL. Ministério da Saúde. Sobre a Doença: O que é a covid-19? [Brasília]: Ministério da Saúde, 2020. Disponível em: https://coronavirus.saude.gov.br/sobre-a-doenca#o-que-e-covid. Acesso em: 10 mar. 2020.
DASA ANALYTICS. Dados COVID-19. 12 dez. 2021. Disponível em: https://dadoscoronavirus.dasa.com.br. Acesso em: 18 mar. 2021.
FALAVIGNA, M. et al. Diretrizes para o tratamento farmacológico da COVID-19. Consenso da Associação de Medicina Intensiva Brasileira, da Sociedade Brasileira de Infectologia e da Sociedade Brasileira de Pneumologia e Tisiologia. Rev. Bras. Ter. Intensiva, São Paulo, v. 32, n. 2, p. 166-196, jun. 2020. DOI: https://doi.org/10.5935/0103-507x.20200039. Disponível em: http://rbti.org.br/artigo/detalhes/0103507X-32-2-1. Acesso em: 9 fev. 2023.
FANTINI, J. et al. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents, v. 55, n. 5, May 2020. DOI: https://doi.org/10.1016/j.ijantimicag.2020.105960. Disponível em: https://www.sciencedirect.com/science/article/pii/S0924857920301102?via%3Dihub. Acesso em: 9 fev. 2023.
FREITAS, A. R. R.; NAPIMOGA, M.; DONALISIO, M. R. Assessing the severity of covid-19. Epidemiol. Serv. Saúde, Brasília, v. 29, n. 2, e2020119, maio 2020. DOI: https://doi.org/10.5123/s1679-49742020000200008. Disponível em: https://www.scielo.br/j/ress/a/TzjkrLwNj78YhV4Bkxg69zx/?lang=en. Acesso em: 9 fev. 2023.
GOLDSMITH, L. A. et al. Dermatologia de Fitzpatrick em Medicina Geral. 8. ed. McGraw Hill, 2012. Disponível em: https://accessmedicine.mhmedical.com/content.aspx?bookid=392§ionid=41138688. Acesso em: 21 ago. 2022.
HUI, D. S. et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China. International Journal of Infectious Diseases, n. 91, p. 264-266, 2020. DOI: https://doi.org/10.1016/j.ijid.2020.01.009. Disponível em: https://www.sciencedirect.com/science/article/pii/S1201971220300114?via%3Dihub. Acesso em: 9 fev. 2023.
IMOTO, A. M. et al. Cloroquina e Hidroxicloroquina no tratamento da COVID-19: Sumário de Evidências. Comunicação em Ciências da Saúde, v. 31, n. Suppl I, p. 17-30, 2020. Disponível em: https://revistaccs.escs.edu.br/index.php/comunicacaoemcienciasdasaude/article/view/653. Acesso em: 9 fev. 2023.
IMPERADOR, C. H. L. et al. Cloroquina e hidroxicloroquina associado ao zinco e/ou azitromicina na COVID-19. ULAKES Journal of Medicine, v. 1, p. 67-73, 2020. Disponível em: https://revistas.unilago.edu.br/index.php/ulakes/article/view/258. Acesso em: 9 fev. 2023.
JUURLINK, D. N. Safety considerations with chloroquine, hydroxychloroquine, and azithromycin in the management of SARS-CoV-2 infection. CMAJ, 27, v. 192, n. 17, 2020. DOI: https://doi.org/10.1503/cmaj.200528. Disponível em: https://www.cmaj.ca/content/192/17/E450. Acesso em: 9 fev. 2023.
MENEZES, C. R.; SANCHES, C.; CHEQUER, F. M. D. Efetividade e toxicidade da cloroquina e da hidroxicloroquina associada (ou não) à azitromicina para tratamento da COVID-19. O que sabemos até o momento? Revista de saúde e ciências biológicas, v. 8, n. 1, p. 1-9, 2020. DOI: https://doi.org/10.12662/2317-3076jhbs.v8i1.3206.p1-9.2020. Disponível em: https://periodicos.unichristus.edu.br/jhbs/article/view/3206. Acesso em: 9 fev. 2023.
OPAS. Organização Pan-Americana de Saúde. Folha informativa covid-19. Escritório da OPAS e da OMS no Brasil. Atualizado em 12 fev. 2021. Disponível em: https://www.paho.org/pt/covid19. Acesso em: 9 fev. 2023.
PACHECO, T. J. A. et al. Panorama mundial de estudos com a hidroxicloroquina para o tratamento da COVID-19. Revista de saúde e ciências biológicas, p. 1-4, 2020. DOI: https://doi.org/10.12662/2317-3076jhbs.v8i1.3288.p1-4.2020. Disponível em: https://periodicos.unichristus.edu.br/jhbs/article/view/3288. Acesso em: 9 fev. 2023.
PAULA, C. E. R. et al. Determinação Espectrofotométrica de Azitromicina em Formulações Farmacêuticas Empregando a Reação com Alizarina. Rev. Virtual Quim., v. 11, n. 4, p. 1081-1096, 2019. Disponível em: https://rvq-sub.sbq.org.br/index.php/rvq/article/view/2483. Acesso em: 9 fev. 2023.
SANDMAN, Z.; IQBAL, O. A. Azithromycin. Treasure Island (FL): Stat Pearls Publishing, 2020. (Atualizado em 30 de outubro de 2020). Disponível em: http://www.ncbi.nlm.nih.gov/books/NBK557766/. Acesso em: 30 out. 2022.
TAREK, M.; SAVARINO, A. Pharmacokinetic bases of the hydroxychloroquine response in COVID-19: implications for therapy and prevention. European Journal of Drug Metabolism and Pharmacokinetics, v. 45, p. 715-723, abr. 2020. DOI: https://doi.org/10.1007/s13318-020-00640-6. Disponível em: https://link.springer.com/article/10.1007/s13318-020-00640-6. Acesso em: 9 fev. 2023.
UZUNIAN, A. Coronavírus SARS-CoV-2 and Covid-19. Jornal Brasileiro de Patologia e Medicina Laboratorial [online], v. 56, e3472020, 2020. DOI: https://doi.org/10.5935/1676-2444.20200053. Disponível em: https://www.scielo.br/j/jbpml/a/Hj6QN7mmmKC4Q9SNNt7xRhf/?lang=en. Acesso em: 9 fev. 2023.
Published
Issue
Section
License
Copyright (c) 2023 Anders Teixeira Gomes, Núbia da Silva Cardoso Nunes, Maria Alice dos Santos Almeida de Oliveira
This work is licensed under a Creative Commons Attribution 4.0 International License.
The authors of the manuscript submitted to Vértices, hereby represented by the corresponding author, agree to the following terms:
The authors retain the copyright and grant Vértices the right of first publication.
At the same time the work is licensed under the Creative Commons Attribution 4.0 International License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon its content for any legal purpose, even commercially, provided the original work is properly cited.
Authors will not receive any material reward for the manuscript and Essentia Editora will make it available online in Open Access mode, through its own system or other databases.
Authors are authorized to enter into additional contracts separately for non-exclusive distribution of the version of the work published in Vértices (eg, publish in institutional repository or as book chapter), with acknowledgment of authorship and initial publication in this journal.
Authors are permitted and encouraged to disseminate and distribute the post-print (ie final draft post-refereeing) or publisher's version/PDF at online information sources (eg, in institutional repositories or on their personal page) at any time after the first publication of the article by Vértices.
Essentia Editora may make normative, orthographic and grammatical changes in the originals in order to maintain the standard language, with the final consent of the authors.
The content and opinions expressed in the manuscript are the sole responsibility of the author (s).
How to Cite
1.png)
